Nventa Biopharmaceuticals Corp.
Stressgen Biotechnologies Corporation (TSX:SSB) (with its subsidiaries, ?Stressgen? or the ?Company?) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative stress protein-based immunotherapeutics, also known as therapeutic vaccines. These therapeutic vaccines are created using the Company?s proprietary CoVal? fusion product technology, which covalently link stress proteins (also known as heat shock proteins) to disease specific antigens. The Company?s lead candidate, HspE7, targets a broad spectrum of human papillomavirus (HPV) related diseases. The Company has also initiated research studies or is evaluating other CoVal? fusion product candidates for the treatment of hepatitis B, herpes simplex, and Hepatitis C